New hope for Tough-to-Treat breast cancer: two drugs vs. one
Disease control
Recruiting now
This study is testing if combining two drugs, capecitabine and elacestrant, works better than just capecitabine alone for people with advanced, hormone-sensitive breast cancer. It's for patients whose cancer has stopped responding to a common class of prior medications. The main …
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC